A constrained disorder principle-based second-generation artificial intelligence digital medical cannabis system: A real-world data analysis

Le résumé fourni par la source

Introduction: Adhering to treatment plans can be challenging for medical cannabis patients. According to the constrained-disorder principle (CDP), biological systems are defined by their degree of variability. CDP-based second-generation artificial intelligence (AI) systems use personalized variability signatures to improve chronic medication response. Aim: We retrospectively analyzed real-world data regarding chronic pain patients using the second generation of artificial intelligence systems to improve adherence to medical cannabis and increase its effectiveness. Design and methods: A retrospective analysis of real-world data of 27 patients using prescribed medical cannabis for chronic pain was conducted. Patients received treatment according to a regimen provided by the CDP-based second-generation AI Altus Care™ app that managed the product's dosage and administration times. The app offers a therapeutic regimen by varying dosages and administration times within predefined ranges. We included 16 patients who participated for more than a week. We assessed adherence to therapy and clinical response in real life based on pain scale measurements. Results: The patients were followed up for 64 days (30-189). Second-generation, AI-based, personalized regimens had a high engagement rate and adherence. 50% of patients showed a high compliance rate. Chronic pain improved in patients who reported their pain score. Summary: This preliminary real-world data analysis suggests that an algorithm-based approach using a second-generation AI system may enhance the adherence to and clinical effectiveness of medical cannabis. These findings require confirmation through prospective controlled studies.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.